Delivery Order SPE2DB22D3301-SPE2DB25FZ1LR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,173.50 to AmerisourceBergen Drug Corp for the supply of Ivabradine HCl 5 mg tablets (60-count units) on September 16, 2025, with completion expected by September 17, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ivabradine HCL 5 mg tablets (60-count units) with a ceiling value of $3,598.88. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, for the supply of Ivabradine HCL 5 mg tablets in a 60-count quantity. The contract, executed on September 26, 2025, carries a ceiling value of $19,626.23 and is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be completed by September 29, 2025, reflecting the expedited nature of this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,718.01 to AmerisourceBergen Drug Corp for the supply of Ivabradine HCl 5 mg tablets (60-count package) on September 11, 2025, with an ultimate completion date of September 12, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ivabradine HCL 5 mg tablets (60-count units) with a ceiling value of $19,104.45. This is a firm fixed-price, non-set-aside delivery order that will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 11, 2025. The contract represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency awarded a $3,992.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ivabradine HCl 5 mg tablets (60-count). This non-set-aside contract is scheduled for completion by August 1, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $8,373.23 delivery order to AmerisourceBergen Drug Corp for Ivabrine HCL 5 mg tablets (60-count units) with an ultimate completion date of July 30, 2025. This non-set-aside, firm fixed-price contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The contractor will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of Ivabradine HCL 5 mg tablets, a pharmaceutical product, with a ceiling value of $12,095.62 and a completion date of June 5, 2025. This delivery order contract is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the...
- This federal contract award to Amerisourcebergen Drug Corp was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of Ivabradine HCl 5mg tablets. The contract is a $1,718.01 firm fixed price delivery order, with an ultimate completion date of August 22, 2024. The award date was August 21, 2024, and there was no set-aside designation used. This order is likely part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp. The $5,655.07 firm fixed-price delivery order contract is for the supply of 4565405881 - Ivabradine HCL 5 mg Tablets in 60-count packages. The contract has an ultimate completion date of August 12, 2024 and was awarded on August 9, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ1LRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ivabradine HCL 7.5 mg tablets (60-count units) under a firm fixed-price contract valued at $12,159.83. The award was made on September 24, 2025, with an ultimate completion date of September 25, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. The parent IDC enables AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. Ivabradine is a cardiac medication used to treat heart failure and angina, representing a critical medical commodity within the company's pharmaceutical distribution portfolio for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 9/24/25 |